Loading...

PRLD PRELUDE THERAPEUTICS INC Capital Structure Changes 8-K Filing

PRLD

PRLD

PRELUDE THERAPEUTICS INC

(PRLD)

2026 8-K

Stock Sale Agreement

Financial Results Announced

FDA Approval Received

Investor Presentation

Financial Results Announced

Exclusive Option Agreement

Compliance Regained

Financial Results Update

Financial Statements

Product Expansion

Financial Results

CFO Appointment

Strategic Partnership

Financial Results

Clinical Data Update

Clinical Data Release

ESMO Announcement

Financial Results

Annual Meeting of Stockholders

Presentation and Educationa...

Appointment and Stock Optio...

Financial Results Announcement

Departure of Chief Financia...

Financial Results Announcement

Securities Purchase Agreement

Financial Results Announcement

Earnings Reports

Annual Meeting Results

Investor Conferences

Entry into a Material Defin...

Financial Results and Inves...

Sales Agreement with Jeffer...

Financial Results and Colla...

Investor Presentation

Amended and Restated Bylaws

Investor Presentation

External Links:

Prelude Therapeutics Inc filed an 8-K on March 12, 2026, to announce a prospectus supplement allowing them to sell up to $25 million of their common stock through Jefferies LLC, based on a previously disclosed agreement for up to $75 million.

AI Assistant

PRELUDE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.